Ambitious Schedule For OTC Monograph Updates On FDA Unified Agenda
This article was originally published in The Tan Sheet
Executive Summary
Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.
You may also be interested in...
E-Cigarette Workshops Aim To Fill Information Gaps Prior To FDA Regulation
The first of three workshops, Dec. 10-11, will focus on device designs, liquid nicotine and other ingredients, aerosol constituents, packaging, constituent labeling and environmental impact. The workshops are not for commenting on a proposed rule deeming cigars, pipe tobacco and electronic nicotine delivery devices subject to FDA’s authority.
E-Cigarette Workshops Aim To Fill Information Gaps Prior To FDA Regulation
The first of three workshops, Dec. 10-11, will focus on device designs, liquid nicotine and other ingredients, aerosol constituents, packaging, constituent labeling and environmental impact. The workshops are not for commenting on a proposed rule deeming cigars, pipe tobacco and electronic nicotine delivery devices subject to FDA’s authority.
OTC Benzocaine Needs Label Warning, Indication Change – Public Citizen
In a citizen petition the group asks FDA to remove teething for children 2 years and older as an indication for some benzocaine products and require a label warning for OTC monograph benzocaine products concerning the risk of methemoglobinemia.